Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort study.

Item

http://www.wikidata.org/entity/Q42199901

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Switching to emtricitabine, te ...... cted patients: a cohort study.

@en

Switching to emtricitabine, te ...... cted patients: a cohort study.

@nl

type

Item

label

Switching to emtricitabine, te ...... cted patients: a cohort study.

@en

Switching to emtricitabine, te ...... cted patients: a cohort study.

@nl

prefLabel

Switching to emtricitabine, te ...... cted patients: a cohort study.

@en

Switching to emtricitabine, te ...... cted patients: a cohort study.

@nl

P1476

Switching to emtricitabine, te ...... cted patients: a cohort study.

@en

P2093

C Bernard-Henry

http://www.w3.org/2001/XMLSchema#string

C Cheneau

http://www.w3.org/2001/XMLSchema#string

D Rey

http://www.w3.org/2001/XMLSchema#string

E de Mautort

http://www.w3.org/2001/XMLSchema#string

M Baldeyrou

http://www.w3.org/2001/XMLSchema#string

M Partisani

http://www.w3.org/2001/XMLSchema#string

M Priester

http://www.w3.org/2001/XMLSchema#string

M-L Batard

http://www.w3.org/2001/XMLSchema#string

P Gantner

http://www.w3.org/2001/XMLSchema#string

P Muret

http://www.w3.org/2001/XMLSchema#string

P2860

Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.

Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs.

Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.

Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.

Impact of food and different meal types on the pharmacokinetics of rilpivirine.

Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.

Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy.

P304

132-136

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/HIV.12183

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-08-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264828898

http://www.w3.org/2001/XMLSchema#string

P698

25124291

http://www.w3.org/2001/XMLSchema#string

P921

virology